Journal Watch · Cell Reports Medicine · 2026

Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers.

Together, we establish that oncRNAs have potential roles in tumor progression and clinical utility in liquid biopsies for tumor-naive minimum residual disease monitoring.

Wang J, Suh JM, Woo BJ et al.Cell Reports Medicine3 min readPharma relevance 65/100

DOI: 10.1016/j.xcrm.2025.102577PMID: 41579861Study type: cohort / observational clinical study

TL;DR

Together, we establish that oncRNAs have potential roles in tumor progression and clinical utility in liquid biopsies for tumor-naive minimum residual disease monitoring.

Key findings

  • Leveraging large-scale in vivo genetic screens in xenografted mice, we functionally identify driver oncRNAs in multiple tumor types.
  • In a retrospective study across 192 breast cancer patients, we show that oncRNAs are reliably detected in blood and that changes in cell-free oncRNA burden predict both short-term and long-term clinical outcomes.
  • Together, we establish that oncRNAs have potential roles in tumor progression and clinical utility in liquid biopsies for tumor-naive minimum residual disease monitoring.

What they did

We show that oncRNA binary presence-absence patterns represent a digital molecular barcode that captures cancer type and subtype identities. Importantly, this barcode is partially accessible from the cell-free space as cancer cells secrete a subset of oncRNAs.

Full abstract (original)

Background: From extrachromosomal DNA to neo-peptides, reprogramming of cancer genomes leads to the emergence of cancer state-specific molecules. Here, we systematically identify and characterize a large repertoire of orphan non-coding RNAs (oncRNAs), a class of cancer-emergent small RNAs, across 32 tumor types.

What they did: We show that oncRNA binary presence-absence patterns represent a digital molecular barcode that captures cancer type and subtype identities. Importantly, this barcode is partially accessible from the cell-free space as cancer cells secrete a subset of oncRNAs.

Results & conclusions: Leveraging large-scale in vivo genetic screens in xenografted mice, we functionally identify driver oncRNAs in multiple tumor types. In a retrospective study across 192 breast cancer patients, we show that oncRNAs are reliably detected in blood and that changes in cell-free oncRNA burden predict both short-term and long-term clinical outcomes. Together, we establish that oncRNAs have potential roles in tumor progression and clinical utility in liquid biopsies for tumor-naive minimum residual disease monitoring.

Abstract © the authors / Cell Reports Medicine (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.xcrm.2025.102577 · PubMed 41579861.

Why it matters for pharma & biotech

  • Relevant to General & Medicine teams tracking Cell Reports Medicine for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Cell Reports Medicine study find?

Together, we establish that oncRNAs have potential roles in tumor progression and clinical utility in liquid biopsies for tumor-naive minimum residual disease monitoring.

What type of study is this?

It is a cohort / observational clinical study, published in Cell Reports Medicine in 2026. We show that oncRNA binary presence-absence patterns represent a digital molecular barcode that captures cancer type and subtype identities.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.xcrm.2025.102577. PubMed ID: 41579861. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Wang J, Suh JM, Woo BJ et al.. Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers.. Cell Reports Medicine (2026). DOI: 10.1016/j.xcrm.2025.102577.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/systematic-annotation-of-orphan-rnas-reveals-blood-accessible-molecular-102577/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides